PE20011177A1 - LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA - Google Patents

LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA

Info

Publication number
PE20011177A1
PE20011177A1 PE2001000216A PE2001000216A PE20011177A1 PE 20011177 A1 PE20011177 A1 PE 20011177A1 PE 2001000216 A PE2001000216 A PE 2001000216A PE 2001000216 A PE2001000216 A PE 2001000216A PE 20011177 A1 PE20011177 A1 PE 20011177A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidines
methyl
alkylpyride
cycline
Prior art date
Application number
PE2001000216A
Other languages
English (en)
Spanish (es)
Inventor
Richard John Booth
Scott Norman Vanderwel
Peter Laurence Toogood
Ellen Myra Dobrusin
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20011177A1 publication Critical patent/PE20011177A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2001000216A 2000-03-06 2001-03-05 LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA PE20011177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
PE20011177A1 true PE20011177A1 (es) 2001-11-23

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000216A PE20011177A1 (es) 2000-03-06 2001-03-05 LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA

Country Status (36)

Country Link
EP (1) EP1268476A1 (is)
JP (1) JP2003528101A (is)
KR (1) KR20020075805A (is)
CN (1) CN1422268A (is)
AP (1) AP2002002643A0 (is)
AR (1) AR034119A1 (is)
AU (1) AU2001233028A1 (is)
BG (1) BG107161A (is)
BR (1) BR0109056A (is)
CA (1) CA2401368A1 (is)
CO (1) CO5280200A1 (is)
CR (1) CR6736A (is)
CZ (1) CZ20022929A3 (is)
DZ (1) DZ3308A1 (is)
EA (1) EA200200802A1 (is)
EE (1) EE200200506A (is)
GT (1) GT200100037A (is)
HN (1) HN2001000040A (is)
HR (1) HRP20020798A2 (is)
HU (1) HUP0300136A2 (is)
IL (1) IL151480A0 (is)
IS (1) IS6524A (is)
MA (1) MA26881A1 (is)
MX (1) MXPA02008535A (is)
NO (1) NO20024235L (is)
NZ (1) NZ520962A (is)
OA (1) OA12227A (is)
PA (1) PA8513201A1 (is)
PE (1) PE20011177A1 (is)
PL (1) PL358271A1 (is)
SK (1) SK12472002A3 (is)
SV (1) SV2001000338A (is)
TN (1) TNSN01036A1 (is)
WO (1) WO2001070741A1 (is)
YU (1) YU66502A (is)
ZA (1) ZA200207110B (is)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
HU229604B1 (en) * 2001-02-12 2014-02-28 Hoffmann La Roche 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
CN1503797A (zh) 2001-02-26 2004-06-09 田边制药株式会社 吡啶并嘧啶或二氮杂萘衍生物
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
PL220952B1 (pl) 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
ATE370952T1 (de) 2002-04-19 2007-09-15 Smithkline Beecham Corp Neue verbindungen
ATE360015T1 (de) 2002-07-31 2007-05-15 Critical Outcome Technologies Protein tyrosin kinase inhibitoren
EP1551824B1 (en) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
DE602004005238T2 (de) 2003-11-13 2007-11-08 F. Hoffmann-La Roche Ag Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Plk阻害剤としての新規プテリジノン
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
US7479558B2 (en) 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EP2322523B1 (en) * 2005-10-07 2019-01-02 Exelixis, Inc. Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
MEP8009A (en) 2006-09-15 2011-12-20 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
CA2665384A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
WO2008124323A1 (en) * 2007-04-03 2008-10-16 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
DK2168966T3 (en) * 2007-06-15 2017-01-23 Msd Kk BICYCLOANILIN DERIVATIVES
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
JP5537439B2 (ja) 2007-12-19 2014-07-02 アムジエン・インコーポレーテツド 細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
KR20120104200A (ko) * 2009-10-09 2012-09-20 아프락시스 인코포레이티드 Cns 장애의 치료를 위한 8­에틸­6­(아릴)피리도[2,3­d]피리미딘­7(8h)­온
CA2784749C (en) * 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
PT2600719E (pt) * 2010-08-05 2014-12-22 Univ Temple 8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
ES2645508T3 (es) 2010-11-29 2017-12-05 OSI Pharmaceuticals, LLC Inhibidores de cinasa macrocíclica
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
HUE033019T2 (en) * 2011-05-17 2017-11-28 Principia Biopharma Inc Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
PL3431475T3 (pl) * 2013-02-21 2021-09-13 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
AU2015296322B2 (en) * 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
ES2876411T3 (es) 2016-08-15 2021-11-12 Pfizer Inhibidores de piridopirimdinona CDK2/4/6
CN110809576B (zh) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 Fgfr激酶抑制剂和药物用途
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
TW202035406A (zh) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 作為cdk-hdac雙通路抑制劑的雜環化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
AU2022234998A1 (en) * 2021-03-08 2023-10-12 Jinan University Pyridopyrimidine compounds and applications thereof
WO2024056091A1 (zh) * 2022-09-16 2024-03-21 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
HUP0102514A3 (en) * 1998-05-26 2002-03-28 Warner Lambert Co Pyrido-pyrimidin and pyrimido-pyrimidin derivatives as inhibitors of cellular proliferation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
MXPA02008535A (es) 2002-12-13
NZ520962A (en) 2003-09-26
SK12472002A3 (sk) 2003-04-01
WO2001070741A1 (en) 2001-09-27
ZA200207110B (en) 2003-12-04
DZ3308A1 (fr) 2001-09-27
MA26881A1 (fr) 2004-12-20
TNSN01036A1 (en) 2005-11-10
BG107161A (en) 2003-06-30
EA200200802A1 (ru) 2003-02-27
NO20024235L (no) 2002-11-05
CA2401368A1 (en) 2001-09-27
IL151480A0 (en) 2003-04-10
BR0109056A (pt) 2003-06-03
IS6524A (is) 2002-08-23
CZ20022929A3 (cs) 2003-02-12
CR6736A (es) 2004-03-10
HUP0300136A2 (en) 2003-05-28
KR20020075805A (ko) 2002-10-05
OA12227A (en) 2004-03-18
JP2003528101A (ja) 2003-09-24
GT200100037A (es) 2002-03-04
AU2001233028A1 (en) 2001-10-03
HN2001000040A (es) 2001-09-06
EE200200506A (et) 2004-02-16
NO20024235D0 (no) 2002-09-05
CN1422268A (zh) 2003-06-04
HRP20020798A2 (en) 2004-02-29
PA8513201A1 (es) 2003-06-30
AR034119A1 (es) 2004-02-04
PL358271A1 (en) 2004-08-09
SV2001000338A (es) 2001-11-30
CO5280200A1 (es) 2003-05-30
AP2002002643A0 (en) 2002-12-31
EP1268476A1 (en) 2003-01-02
YU66502A (sh) 2005-09-19

Similar Documents

Publication Publication Date Title
PE20011177A1 (es) LAS 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORAS DE LAS CINASAS DE TIROSINA Y QUE DEPENDEN DE LA CICLINA
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
PE20021096A1 (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo[2,3-d]pirimidina como inhibidores de la tirosina-cinasa igf-ir
PE20021010A1 (es) Derivados espirociclicos como inhibidores de fosfodiesterasa-7
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
MXPA02011426A (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa.
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
PE20030208A1 (es) Derivados de indirubina que contienen azufre, su preparacion y uso
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
UY27604A1 (es) Compuestos químicos.
HN2002000067A (es) Inhibidores de la rho - quinasa.
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
UY26782A1 (es) Derivados del benzotiazol
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
PA8432901A1 (es) Compuestos de piridilpirrol
ATE302775T1 (de) Carbolinderivate
PE20030735A1 (es) Derivados de benzotiazol
SV2003001173A (es) 1-alquil o 1-cicloalquil-triazolo [4,3-a] quinazolin-5- onas como inhibidoras de fosfodiesterasa
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5170529A1 (es) Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida
ECSP055693A (es) Proceso para la síntesis de intermediarios útiles para la síntesis de inhibidores de la tubulina
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
ATE346067T1 (de) Carbolinderivate
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FC Refusal